Hongwei Cheng

2.4k total citations
15 papers, 906 citations indexed

About

Hongwei Cheng is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hongwei Cheng has authored 15 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Hongwei Cheng's work include Sarcoma Diagnosis and Treatment (5 papers), Cancer-related molecular mechanisms research (3 papers) and RNA modifications and cancer (2 papers). Hongwei Cheng is often cited by papers focused on Sarcoma Diagnosis and Treatment (5 papers), Cancer-related molecular mechanisms research (3 papers) and RNA modifications and cancer (2 papers). Hongwei Cheng collaborates with scholars based in Canada, United States and China. Hongwei Cheng's co-authors include Yuzhuo Wang, Torsten O. Nielsen, Tingyuan Yang, Yanlan Liu, Jinjun Shi, Xiaoyuan Ji, Diana Askhatova, Amal M. El-Naggar, Poul H. Sorensen and Syam Prakash Somasekharan and has published in prestigious journals such as Angewandte Chemie International Edition, The Journal of Cell Biology and Oncogene.

In The Last Decade

Hongwei Cheng

14 papers receiving 895 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hongwei Cheng Canada	13	563	256	208	176	130	15	906
Chao Jing China	16	517 0.9×	269 1.1×	86 0.4×	122 0.7×	123 0.9×	34	826
Teng Hou China	17	525 0.9×	319 1.2×	78 0.4×	99 0.6×	61 0.5×	41	861
Huiqin Sun China	15	349 0.6×	215 0.8×	128 0.6×	251 1.4×	154 1.2×	18	849
Yan Du China	9	351 0.6×	309 1.2×	156 0.8×	258 1.5×	79 0.6×	22	873
Weiyuan Wang China	18	530 0.9×	247 1.0×	120 0.6×	59 0.3×	71 0.5×	67	880
Shangzhi Xie China	14	565 1.0×	361 1.4×	55 0.3×	178 1.0×	74 0.6×	33	925
Haoyu Ruan China	14	656 1.2×	482 1.9×	125 0.6×	98 0.6×	33 0.3×	22	942
Jinxiang Tan China	14	429 0.8×	253 1.0×	81 0.4×	129 0.7×	46 0.4×	21	818
Anna Degrassi Italy	17	226 0.4×	145 0.6×	80 0.4×	144 0.8×	59 0.5×	26	736

Countries citing papers authored by Hongwei Cheng

Since Specialization

Citations

This map shows the geographic impact of Hongwei Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongwei Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongwei Cheng more than expected).

Fields of papers citing papers by Hongwei Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongwei Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongwei Cheng. The network helps show where Hongwei Cheng may publish in the future.

Co-authorship network of co-authors of Hongwei Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Hongwei Cheng. A scholar is included among the top collaborators of Hongwei Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongwei Cheng. Hongwei Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

Wang, Yiping, Lei Ye, Yicheng Jiang, et al.. (2025). Dual-pathway targeted therapy for Parkinson's disease: Biomimetic nanosomes inhibit ferroptosis and pyroptosis through NLRP3 inflammasome regulation. Bioactive Materials. 51. 825–840. 3 indexed citations

2.

Peng, Ye, et al.. (2025). Hydrogel-based tumor embolization and synergistic therapeutic strategies. Bioactive Materials. 59. 17–44.

3.

Wilkes, David, Verena Sailer, Hui Xue, et al.. (2017). A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Molecular Case Studies. 3(5). a001487–a001487. 19 indexed citations

4.

Liu, Yanlan, Xiaoyuan Ji, Diana Askhatova, et al.. (2017). Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angewandte Chemie. 130(6). 1526–1529. 35 indexed citations

5.

Liu, Yanlan, Xiaoyuan Ji, Diana Askhatova, et al.. (2017). Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angewandte Chemie International Edition. 57(6). 1510–1513. 184 indexed citations

6.

Crea, Francesco, Xinpei Ci, Hongwei Cheng, et al.. (2016). The Role of Epigenetics and Long Noncoding RNA MIAT in Neuroendocrine Prostate Cancer. Epigenomics. 8(5). 721–731. 95 indexed citations

7.

Somasekharan, Syam Prakash, Amal M. El-Naggar, Poul H. Sorensen, Yuzhuo Wang, & Hongwei Cheng. (2016). An Aqueous Extract of Marine Microalgae Exhibits Antimetastatic Activity through Preferential Killing of Suspended Cancer Cells and Anticolony Forming Activity. Evidence-based Complementary and Alternative Medicine. 2016(1). 9730654–9730654. 26 indexed citations

8.

Parolia, Abhijit, Francesco Crea, Hui Xue, et al.. (2015). The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Molecular Cancer. 14(1). 46–46. 73 indexed citations

9.

Somasekharan, Syam Prakash, Amal M. El-Naggar, Gabriel Leprivier, et al.. (2015). YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. The Journal of Cell Biology. 208(7). 913–929. 209 indexed citations

10.

Xue, Hui, Hongwei Cheng, Dong Lin, et al.. (2014). TheBIRC6gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget. 5(16). 6896–6908. 26 indexed citations

11.

Mendoza‐Naranjo, Ariadna, Amal M. El-Naggar, Daniel Wai, et al.. (2013). ERBB 4 confers metastatic capacity in Ewing sarcoma. EMBO Molecular Medicine. 5(7). 1087–1102. 71 indexed citations

12.

Su, Le, Hongwei Cheng, Arthur V. Sampaio, Torsten O. Nielsen, & T. Michael Underhill. (2010). EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene. 29(30). 4352–4361. 50 indexed citations

13.

Cheng, Hongwei, Paul W. Clarkson, Dongxia Gao, et al.. (2010). Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor. Sarcoma. 2010. 1–7. 27 indexed citations

14.

Cheng, Hongwei, Erika Mehl, Shuzhen Liu, et al.. (2009). Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Human Pathology. 40(9). 1244–1251. 39 indexed citations

15.

Liu, Shuzhen, Hongwei Cheng, Wanda Kwan, Joanna M. Lubieniecka, & Torsten O. Nielsen. (2008). Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Molecular Cancer Therapeutics. 7(6). 1751–1761. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact